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to its poor in vitro activity against M. kansasii. Improved thera-
peutic regimens for this pathogen would be useful. The purpose of
the present study was to evaluate the comparative in vitro activi-
ties of TR-1710, a new pyrimidoindole DNA gyraseB inhibitor, and
moxiﬂoxacin, a GyrA inhibitor, against twenty two isolates of M.
kansasii. It is unlikely that cross resistance will be a problem with
gyrase inhibitors targeting different enzyme subunits.
Methods&Materials:TR-1710andmoxiﬂoxacinwereobtained
from Cubist Pharmaceuticals (San Diego, CA) and Bayer Pharma-
ceuticals (West Haven, CT) respectively. These compounds were
dissolved in DMSO to a concentration of 1mg/ml prior to freez-
ing at -200C. They were tested in Middlebrook 7H9 broth, pH6.6
supplemented with 10% Middlebrook albumin-dextrose-catalase
enrichmentat2g/ml–0.002g/ml inpolystyrene96-well round-
bottom microtiter plates. To each well, 50l of mycobacterial cell
suspension was added to yield an initial concentration of about 1
x 105 CFU/ml (range for various isolates tested was 3.8 x103 – 1.2
x 106CFU/ml). Plates were incubated at 370C in ambient air for 7 -
10 days prior to reading.
Results:TR-1710andmoxiﬂoxacinhad similar activities against
M. kansasii in vitro. The MIC50/MIC90 (g/ml) of TR-1710 and
moxiﬂoxacin were 0.03/0.06 and 0.06/0.50 respectively.
Conclusion: Based on TR-1710’s promising in vitro activity, it
would be interesting to evaluate the comparative activities of TR-
1710 and moxiﬂoxacin in a murine model of M. kansasii infection,
as the next step in deﬁning the potential of gyrase inhibitors in the
treatment of these infections in humans.
http://dx.doi.org/10.1016/j.ijid.2014.03.838
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inhibitors protect kidneys during vancomycin
administration?
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Background:Vancomycin iswidely used for treatment ofMRSA
infection. For safe use of vancomycin, it is important to employ
the therapeutic drug monitoring, although renal function can get
worse even by maintaining the safe concentration of vancomycin.
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin
receptor blockers (ARBs) are antihypertensives which are known
to block renin-angiotensin-aldosteron system and to have renal
protecting effect. However, there has been no study investigating
the effect of ACEIs or ARBs on renal protection during vancomycin
administration. In this studywe investigated the inﬂuence of ACEIs
or ARBs on renal function during the vancomycin administration.
Methods & Materials: All the hospitalized patients who receive
vancomycin intravenously in the department of internal medicine
in the Teikyo University hospital from September 2010 to February
2013 were enrolled. Patients who received other potential nephro-
toxic agents, those who stopped receiving vancomycin due to
other reason than renal dysfunction, or those who died during the
treatment were excluded. All the patients were divided into three
groups; ACEI/ARB groups, other antihypertensive group, and non-
antihypertensive group. Clinical backgrounds, trough vancomycin
concentrations, and changes of estimated glomerular ﬁltration
rates (eGFRs) were compared by reviewing medical records. Acute
kidney injury (AKI) was deﬁned as increase in the serum creatinine
concentration of ≥0.3mg/dL from baseline.
Results: Thirty one patients were enrolled in this study.
ACEI/ARB group were nine, other antihypertensive group were
nine, and non-antihypertensive groups were 13. Among clinical
backgrounds, only the ratio of hypertension was lower in the non-
hypertensive group than in the other two groups. Mean trough
vancomycin concentrations were not different between the three
groups (15.3 vs 16.0 vs 14.7g/mL, P=0.86).Mean eGFRs at the van-
comycin initiation and at the vancomycin termination were not
statistically different between the three groups (59.0 vs 57.4 vs
58.8mL/min/1.73m2, P=0.61; 60.5 vs 57.1 vs 57.2mL/min/1.73m2,
P=0.80, respectively). The ratio of AKI was not statistically different
between the three groups (3/9 vs 1/9 vs 1/13, P=0.24).
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Background: Nitroxoline, a hydroxychinolin derivate, is used
for many years for treatment of urinary tract infections (UTI). Four
controlled clinical studies concerning treatment of uncomplicated
UTI (uUTI) not published yet were meta-analysed.
Methods & Materials: The individual patient data (IPD) of 466
females with acute sporadic or acute episodes of recurrent uUTI
of four prospective, controlled, single blind, randomized clinical
studieswith similar protocols using nitroxoline (250mg tid) versus
cotrimoxazole (960mg bid) or norﬂoxacin (400mg bid) as controls
for ﬁve (three studies) or ten (one study) days were meta-analysed
by the same criteria. The primary efﬁcacy was the eradication
of bacteriuria. Success was deﬁned if pretreatment bacteriuria of
≥105CFU/ml was reduced to < 104CFU/ml 7-13 days after end of
therapy (test of cure). Clinical efﬁcacy was determined by elimi-
nation of symptoms and safety by adverse events and laboratory
tests.
Results: A total of 234 patients were treated orally with nitrox-
oline and 232 with the controls. The safety of nitroxoline was very
good and comparable to the controls (total adverse events 9.4% vs
7.8%). In the modiﬁed microbiological ITT set (at least one outcome
result available), in the PP set (test of cure outcome available) and
in the modiﬁed PP set (missing test of cure rated failure) more than
90% of the patients showed eradication of bacteriuria with nitrox-
oline, which also met statistical non-inferiority compared to the
controls (10% non-inferiority margin) in all three evaluation sets.
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The clinical efﬁcacy (reduction of symptoms, global assessment
by patient and physician) was similar between the two treatment
groups.
Conclusion: The IPD meta-analysis using objective parameters
(eliminationof bacteriuria) demonstrated equivalent efﬁcacy (non-
inferiority) of nitroxoline with the controls tested (cotrimoxazole,
norﬂoxacin) in the treatment of uUTI.With a ﬁve (sporadic uUTI) or
ten day (recurrent uUTI) therapy elimination of bacteriuria can be
achieved in over 90% of the patients. Considering the good safety
andefﬁcacyofnitroxoline and theworldwide increaseof resistance
of uropathogens against cotrimoxazole and ﬂuoroquinolones, but
not against nitroxoline within the last 20 years, nitroxoline should
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Background: Tuberculosis (TB) is a major cause of morbidity
andmortalityworldwide. Co-infectionwithHIVand theemergence
of drug-resistant Mycobacterium tuberculosis strains (MDR-and
XDR-TB) has reafﬁrmed TB as a global public health threat. New
therapies are urgently needed. An alternative approach to gen-
erate new TB treatment options in a timely and cost-effective
manner is “repurposing” clinically used drugs with known phar-
maceutical properties. In the course of a screening program [PMID:
21576426], we identiﬁed the in vitro anti-tuberculosis activity of
the anthelmintic avermectins (ivermectin, selamectin, moxidectin
and doramectin) [PMID: 23165468].
Methods & Materials: We performed a literature search on the
pharmacological properties of the avermectins. We integrated this
informationwith our in vitrodata and calculated a theoretical phar-
macodynamic value (AUC/MIC; a measure of drug exposure) to
deﬁne potential in vivo efﬁcacy. We validated our analysis by eval-
uating avermectins in an in vivo model of M. tuberculosis infection.
Results: An AUC/MIC ratio of 10 to 15 was calculated for
bactericidal activity of the avermectins. Due to tolerability and
pharmacokinetic issues the low maximal plasma concentrations
of ivermectin (ng/mL range) resulted in a low calculated exposure
(AUC/MIC < 1). Moxidectin had a longer half-life than ivermectin
and, therefore, the calculated AUC/MIC ratios increased. However,
this was still not enough to provide theoretical in vivo activity. In
contrast, selamectin’s pharmacokinetic properties suggest that it
might be effective in vivo against M. tuberculosis; high plasma con-
centrations (g/mL range), low toxicity (LD50 >1,600mg/kg bw),
and theoretical AUC/MIC ratios are consistentwith potential in vivo
activity. Interestingly, reported concentrations of selamectin in the
lungs (the main site where M. tuberculosis resides) were ca. 2-fold
higher than in plasma, suggesting even higher AUC/MIC ratios at
the site of infection.We therefore tested ivermectin and selamectin
for in vivo activity against M. tuberculosis. Our predictions were
consistent with the in vivo data; while ivermectin at the highest
possible safe dose did not have anti-mycobacterial activity in vivo,
selamectin was active.
Conclusion: This theoretical data analysis supports the poten-
tial of selamectin for TB therapy, including MDR- and XDR-TB, and
warrant further in vivo testing in mouse infection models.
http://dx.doi.org/10.1016/j.ijid.2014.03.841
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The life saving little tip: Intraosseous gas
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Background: Emphysematous osteomyelitis is a rare but ful-
minant disease. Therefore, radiologists should be aware of the
implication of intraosseous gas signs for quick diagnosis.
Methods & Materials: Case: A 55-year-old woman with dia-
betes mellitus and hypertension was admitted to the emergency
department and presented with high fever (40 ◦C), nausea, and
pelvic pain. Physical examination revealed pelvic and pubic ten-
derness on deep palpation. Laboratory data included leukocytosis
(12390/mm3 with 85.5% neutrophilis), high procalcitonin (33.8
ng/ml), C-reactiveprotein (211mg/dl) levels, a high sedimentation
rate (80mm/h), also elevated blood sugar (290mg/dl), and elevated
hemoglobin A1C level (13.4%). Blood cultures were obtained prior
to the initiation of antimicrobial therapy.
Abdominal ultrasonographic examination revealed cholelithi-
asis without gallbladder wall thickening and a small amount of
isolated pelvic free ﬂuid. A subsequent CT of her abdomen and
pelvis showed multiple gas bubbles in the medullary cavity of the
bilateral pubic bones, extending into the anterior acetabulum. A
moderate amount of gas was seen in the soft tissues surrounding
the pubis. Also, marked subcutaneous reticulation and low attenu-
ation areas of subcutaneous gas were detected in the right gluteal
region. MRI conﬁrmed the CT ﬁndings and provided clearer images
of the small abscess formations and the peripubic soft tissue com-
ponent of the infection. CT-guided biopsy of prepubic soft tissue
collection was performed, and Escherichia coli was cultured from
the diagnostic specimen.
Results: Intravenosus (IV) imipenemcilastatin (4×500mg) and
vancomycin (2×1g) was started as an empirical treatment. The
patient underwent urgent surgical debridement of the soft tissue
abscess. All samples (biopsy–surgical specimens and blood cul-
tures) revealed a monomicrobial growth of E. coli. Intravenosus
ciproﬂoxacin (2×400mg) was started based on the antibiogram
results. The ﬁrst 3 weeks of treatment was completed as IV ther-
apy. The patient was discharged with oral antibiotic treatment
(ciproﬂoxacin 2×750mg). The patient’s treatment was completed
in 6 weeks. No complications were seen and she continues to be
followed up.
